- Quality requirements for cascade impactors assigned to batch release testing of a specific drug product; Part III: Implications of Type II error probability
- Cascade impactor stage groupings: Poor decisions from degraded data
- Gaining new insights into pressurized metered dose inhaler (pMDI) design using synchrotron radiation
- The liability of fine particle dose (FPD)
- Quality requirements for cascade impactors assigned to batch release testing of a specific drug product; Part II: The concept of “sufficient” as applied to impactor quality specifications
- Optimizing the role of automation in variability reduction strategies for delivered dose uniformity (DDU) and aerodynamic particle size distribution (APSD) testing of inhaled drug products
- Solid-state physicochemical characterization and microscopy of particles in dry powder inhalers (2019)
- An update on solid-state physicochemical characterization and microscopy of particles in dry powder inhalers
- Quality requirements for cascade impactors assigned to batch release testing of a specific drug product; Part I: A grassroots look
- Applications of automated scanning electron microscopy—energy dispersive spectroscopy (SEM-EDS) for inhalable drug products
- The regulatory landscape for OINDPs—the biggest shake-up in a generation?
- Point of View: Recommendations to a young scientist to pursue inhalation research
- Defining the dosage strength for labeling of DPIs: Use, limitations and relevance of in vitro data
- Combined impactor and x-ray diffraction (XRPD) methodology for characterizing polymorph impurities in inhalation powders
- Progress in particle engineering science: Towards advanced dry powder inhalation systems
- A practical method for eliminating type I and type II errors when assessing the suitability for continued use of a cascade impactor
- Back Page: Humble giant of cascade impactors, Virgil A. Marple; August 16, 1939 to December 24, 2017
- Back Page: A free online tutorial about cascade impaction from the IPAC-RS CI working group
- The Good Cascade Impactor Practice (GCIP) Concept: A systematic approach to risk management of erroneous measurements in the assessment of inhaler emitted aerosol aerodynamic particle size distributions (APSDs)
- The Abbreviated Impactor Measurement (AIM) and Efficient Data Analysis (EDA) concepts: Why they are important and how to work with them
- Surface science and particle interactions in dry powders for inhalation
- Solid-state physicochemical characterization and microscopy of particles in dry powder inhalers (2016)
- Significant advances in laboratory testing of orally inhaled products during the ten-year life of Inhalation
- Particle engineering for inhalation formulation and delivery of biotherapeutics
- Particle engineering by practical and scalable, intensive, mechanical, dry coating processes to develop highly efficient dry powder inhaler formulations
- Overcoming challenges in development of nasal vaccines through intelligent particle engineering
- Obscuring the message: A critical examination of laboratory test methods for orally inhaled products that could lead the user astray: Part 2—Total Emitted Mass (TEM) and related metrics
- New cascade impactor software
- Measuring powder properties
- Measuring particle adhesive ability
- Inverse gas chromatography
- Inspecting used impactors—Practice and principles
- Innovation in analytical tools: More signal and less noise in particle size testing of inhaled products
- Inhalation toxicity of graphene and its derivatives
- Ingredient-specific particle sizing
- Implementing the AIM concept
- Image analysis for particle characterization
- Good practices for Abbreviated Impaction Measurements (AIM) in dry powder inhalers (DPIs)
- From actuation to deposition: Particle sizing techniques for characterizing nasal drug delivery systems
- Evaluating the Alberta Throat: An innovation to support the acquisition of more clinically applicable aerosol aerodynamic particle size distribution (APSD) data in oral inhaled product (OIP) development
- Contributions of mechanical stress on the “frustrated” thermal response of griseofulvin
- Considerations in spray dry drug development for inhalation delivery: An albuterol case study
- The Next Generation Impactor (NGI™)—Manufacturing Control: Part I. Nozzles
- The Next Generation Impactor (NGI™)—Manufacturing Control: Part II. Collection Cups and the Critical Jet-to-Plate Distance
- Comparison between in vitro performance of the Child “Alberta” Idealized Throat and Ph.Eur./USP induction port for the delivery of salbutamol sulfate inhalation aerosol by pressurized metered dose inhaler
- Chemical-selective imaging of adhesive mixtures for inhalation using coherent anti-Stokes Raman scattering (CARS) microscopy
- Characterizing carrier-free DPI formulations
- Cascade Impactors
- Cascade impactor flow control
- Calibrating cascade impactors with particles—Approaches and pitfalls
- Assessing the role of breathing simulators in OIP testing
- Thixotropic sprays: Popular with patients, challenging for developers
- Unveiling dislocations in API crystallinity after mechanical stress due to milling
- Analytical instrumentation for solid state characterization of inhalable formulations
- An approach to particle size stability
- Aerosolized adhesive coating of cascade impactor plates
- Accuracy in the optical inspection of impactor nozzles—More to it than meets the eye
- A novel aerodynamic sizing method for pharmaceutical aerosols using image-based analysis of settling velocities
- A forensic approach to particulate contamination in inhalable drug products
- Testing the equivalence of aerodynamic particle size distributions
- Obscuring the message: A critical examination of laboratory test methods for orally inhaled products that could lead the user astray: Part 1—Aerodynamic Particle Size Distribution (APSD)
- The electrical Next Generation Impactor